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ABSTRACT: Introduction: Duchenne muscular dystrophy (DMD)
subjects 5 years with nonsense mutations were followed for 48
weeks in a multicenter, randomized, double-blind, placebo-con-
trolled trial of ataluren. Placebo arm data (N 5 57) provided
insight into the natural history of the 6-minute walk test (6MWT)
and other endpoints. Methods: Evaluations performed every 6
weeks included the 6-minute walk distance (6MWD), timed func-
tion tests (TFTs), and quantitative strength using hand-held myo-
metry. Results: Baseline age (7 years), 6MWD, and selected
TFT performance are strong predictors of decline in ambulation
(D6MWD) and time to 10% worsening in 6MWD. A baseline
6MWD of <350 meters was associated with greater functional
decline, and loss of ambulation was only seen in those with
baseline 6MWD <325 meters. Only 1 of 42 (2.3%) subjects able
to stand from supine lost ambulation. Conclusion: Findings con-
firm the clinical meaningfulness of the 6MWD as the most
accepted primary clinical endpoint in ambulatory DMD trials.
Muscle Nerve 48: 343–356, 2013
Duchenne muscular dystrophy (DMD) is a dis-
abling and life-threatening X-linked genetic disor-
der caused by defects in the gene for dystrophin
that results in a progressive loss of functional mus-
cle fibers and weakness with stereotypic functional
consequences affecting mobility, progressive mus-
culoskeletal deformities, upper limb impairment,
impaired airway clearance and ventilation, cardio-
myopathy, and premature death.1,2
The past several years have seen increased
interest by biopharmaceutical companies in con-
ducting ground-breaking research and develop-
ment into novel treatment agents for DMD. There
is considerable hope that new disease-modifying
therapies will slow disease progression, stabilize or
improve function, and maintain quality of life. The
DMD population targeted by such trials features
patients who are old enough to be assessed reliably
and still have sufficient muscle fibers available for
therapeutics to demonstrate a measurable benefit
over the typical 1-year clinical trial duration.
Bipedal ambulation constitutes an almost
uniquely human characteristic and is the most com-
monly performed physical activity by humans.3 Pre-
viously, we modified the American Thoracic Society
version of the 6-minute walk test (6MWT) for DMD
and validated the 6-minute walk distance (6MWD)
as a measure of disease progression in ambulatory
DMD patients.4–6 Given that ambulatory compro-
mise is such an important component of the DMD
disease process, improvement in the 6MWD with
treatment relative to placebo constitutes clear evi-
dence of therapeutic value. Thus, rather than being
a surrogate endpoint, a change in the 6MWD can
be defined as an important clinically meaningful
endpoint that directly assesses how an ambulatory
DMD patient functions.7 Evidence documenting the
reliability of the 6MWT and the concurrent validity,
sensitivity, and clinical meaningfulness of longitudi-
nal changes in the 6MWD4–6,8,9 has led to its com-
mon use as the primary clinical endpoint in
ambulatory DMD trials worldwide.
Additional Supporting Information may be found in the online version of
this article.
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Because loss of muscle function in DMD occurs
against the background of normal childhood growth
and development associated with increases in stride
length, children with DMD who are <7 years of age
may show increases in 6MWD over 1 year despite
progressive muscular impairment.6,9,10 Older DMD
subjects demonstrate variable rates of decline in
6MWD. These findings emphasize the importance
of age as a stratification factor in DMD clinical trials
using the 6MWD. In addition, Henricson and col-
leagues10 showed that normalizing the data by con-
verting 6MWD to a percent predicted 6MWD value
may help to distinguish normal growth and develop-
ment from disease-related progression and treat-
ment effects. The results accumulated over the last
several years have shown that the 6MWT offers
advantages in DMD as an integrated global measure
of ambulatory function that is influenced by lower
extremity strength, biomechanical inefficiencies,
endurance, and cardiorespiratory status.11
Longitudinal 6MWD natural history data pro-
vide information on how DMD patient ambulation
changes over time (change scores), as well as an
understanding of how the variability of the 6MWT
(standard deviation) changes over time. This infor-
mation can be used in clinical trial design for
novel therapeutics. Such data for the change score
and the standard deviation (SD) of the change
score allow for more accurate statistical powering
of clinical trials. Furthermore, as we gain under-
standing of the natural history of DMD we will ulti-
mately be able to use these and future data for
patients who receive standard-of-care treatment as
historical controls. This will allow comparisons of
treated subjects with historical controls for deter-
mination of efficacy in trials targeting rare popula-
tions with genetic-based treatments.
To determine the clinical relevance of a treat-
ment effect for a given endpoint one must know
what constitutes a minimal clinically important dif-
ference (MCID). For the 6MWD applied to DMD
this has been estimated to be 30 m using 2 statis-
tical distribution approaches.11 Knowledge of the
MCID difference in 6MWD and the relevant vari-
ability of the change score make it possible to
design clinical trials of appropriate power and size.
The aim of this report of placebo-treated
patients from the phase 2b ataluren clinical trial
(PTC Therapeutics)12,13 is to: (1) determine the
contemporary natural history of common clinical
measures of disease progression in ambulatory
DMD subjects [6MWD, timed function tests
(TFTs), and quantitative strength using hand-held
myometry]; (2) estimate the probability of clini-
cally meaningful disease progression (defined as
persistent 10% worsening in 6MWD) and evaluate
baseline predictors of subsequent 10% worsening;
and (3) assess the relationship between baseline
6MWD and future loss of ambulation.
METHODS
Overall Study Design and Procedures. The natural
history data were derived from the placebo arm of
a phase 2b, international, multicenter, random-
ized, double-blind, placebo-controlled, dose-
ranging study to evaluate the efficacy and safety of
ataluren in ambulatory male patients aged 5
years with nonsense mutation DMD. The study
comprised a 6-week screening period and a 48-
week blinded study drug treatment period. Patients
were stratified by age (<9 or 9 years), use of glu-
cocorticoids (yes or no), and baseline 6MWD
(350 or <350 m), and were randomized 1:1:1 to
receive ataluren, at either a high or low dose, or
matching placebo, daily for 48 weeks. Evaluations
were performed at screening, baseline, and every 6
weeks for 48 weeks.
Participants. The study included DMD patients as
described previoiusly.11 Institutional review
boards/institutional ethics committees and health
authorities approved the study protocol. All
parents/participants provided signed informed
consent/assent before study initiation.
Outcome Measures. The following outcome meas-
ures were obtained during screening, at baseline,
and every 6 weeks during treatment.
6-Minute Walk Test/6-Minute Walk Distance. Am-
bulation was assessed via the 6MWT following
standardized procedures developed at University of
California, Davis,7 by measuring the 6MWD in
meters. The specific details of the modifications to
the 6MWT, reliability, and validity in DMD were
reported previously.5,6,11
Timed Function Tests. TFTs included time
taken to stand from a supine position, time taken
to run/walk 10 m, and time taken to climb or
descend 4 standard-size stairs.14–22 TFTs provide a
measure of functional capability in ambulatory
patients that is complementary to the 6MWT. The
tests are reproducible, simple to administer, and
have a documented response to therapeutic inter-
vention with steroids.17,19,23 A stopwatch was used
to time the 10-meter walk, standing from supine,
and 4-stair climb and descent. Test–retest reliability
of the TFTs in this study have been described
elsewhere.11
Myometry. Upper and lower extremity strength
assessment was performed using a myometer fol-
lowing standardized procedures.24,25 Muscle groups
evaluated included knee flexors and extensors,
elbow flexors and extensors, and shoulder abduc-
tors. Force in pounds was determined. These
parameters were monitored during screening, at
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baseline, and every 6 weeks during treatment.
Methodology and test–retest reliability of the
strength measures have been described
elsewhere.11
Data Analysis. The longitudinal natural history
changes over 48 weeks were analyzed from data
obtained from the 57 placebo-control patients. For
6MWD, percent predicted 6MWD, TFTs, strength
in pounds, mean and SD, change from baseline,
and SD of change from baseline were determined.
Data are reported as mean (SD) in the text and
tables and displayed as mean 6 standard error of
the mean (SEM) in the figures. The statistical pro-
gram used was SAS, version 9.3 (SAS Institute,
Cary, North Carolina).
Percent Predicted 6MWD. To account for
maturational effects such as age, height, and asso-
ciated stride length,5,6,10 we calculated a percent
predicted 6MWD according to the prediction equa-
tion described by Geiger and colleagues.26 This
equation has been validated in DMD and is consist-
ent with the findings of Henricson and col-
leagues10 using the same DMD-modified 6MWT
protocol.
Time to Persistent 10% 6MWD Worsening. Time
to persistent 10% 6MWD worsening was used to
evaluate rates of disease stabilization and progres-
sion and was evaluated using Kaplan–Meier meth-
ods. The time to persistent 10% 6MWD worsening
was defined as the last time that 6MWD was not
10% worse than baseline. For patients who did not
have 10% 6MWD worsening or who were removed
from the study, time to event was censored at the
time of the last 6MWD value. Differences among
strata were tested using a stratified log-rank test.
RESULTS
Patients’ Characteristics. Patient characteristics of
the group under evaluation (N 5 57) are shown in
Table 1. Of the 57 patients, 32 (56%) were <9
years of age, and 34 (60%) had baseline 6MWD of
>350 m. All patients were males, ranging in age
from 5 to 15 years (Table 1). All 3 premature stop
codon types were represented in the study popula-
tion. Forty of 57 DMD patients (70.2%) were on
stable regimens of systemic glucocorticoids for 6
months at the initiation of the study, which con-
sisted of either prednisone, prednisolone, or defla-
zacort used on either daily or intermittent
schedules.
6MWT Compliance and Falls during the Test. As
shown in Table 2, most patients were able to per-
form a valid 6MWT on their first and only attempt.
The frequency of valid 6MWTs exceeded 98%. Fall
data during the 6MWT from screening to the 48-
week evaluation are shown in Table 2. In 93.1% of
tests there were no fall events, and the median
duration of 5 seconds per fall represents only 1.4%
of the 6-minute evaluation time.
Strength Changes by Myometry over 48 Weeks.
Mean strength changes over 48 weeks are shown
for myometry in Figure 1. The mean baseline and
mean change from baseline at 48 weeks were as
follows: knee flexion, 11.06 and 10.38 pounds;
knee extension, 12.96 and 21.85 pounds; elbow
flexion, 8.14 and 20.35 pounds; elbow extension,
6.77 and 20.51 pounds; and shoulder abduction,
5.76 and 20.28 pounds. There were no significant
differences in strength change over 48 weeks for
glucocorticoid-treated versus non–glucocorticoid-
treated patients.
Changes in TFTs over 48 Weeks. For the 40
patients on stable doses of glucocorticoids at the
initiation of the study baseline the TFT results
[mean (SD)] for 6 subjects <7 years and 34 sub-
jects 7 years, respectively, were as follows: time to
rise from supine 5 4.0 s (1.13) and 12.9 s (12.33);
time to climb 4 stairs 5 2.5 s (0.67) and 6.6 s
(6.30); time to run/walk 10 m 5 4.8 s (0.86) and
7.1 s (2.80). Mean changes from baseline 6 SEM
over 48 weeks are plotted in Figure 2a–c. For all
TFTs there was little change over 48 weeks in
patients <7 years of age, whereas for patients 7
years there were greater changes in TFT values. In
general, the SD and SEM of the change scores
from baseline increase over time due to variability
in disease progression.
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Relationship between Changes in 10-Meter Run/Walk
and 6MWD. It is useful to evaluate the relationship
between percent change in 10-m run/walk test and
percent change in 6MWD to establish links
between 6MWD data with longer-term 10-m run/
walk data. Figure 3 shows a strong linear relation-
ship between these 2 different types of ambulation
measurement (r 5 0.89, P < 0.00001).
Relationship between Changes in 6MWD and Percent
predicted 6MWD. There was a very high correla-
tion between baseline 6MWD and baseline percent
predicted 6MWD (r 5 0.94). The correlation at 48
weeks between change from baseline in 6MWD
and change from baseline in percent predicted
6MWD is r 5 0.99. Thus, the percent predicted
6MWD data is not considered to be a separate end-
point but rather is both a maturational and norma-
tive context for the 6MWD, because the measure is
strongly related to stride length and cadence and
age in DMD patients and controls.5,6
Natural History of 6MWD over 48 Weeks. The 1-year
natural history of changes in 6MWD and age- and
height-based percent predicted 6MWD is shown in
Figure 4a and b. Although differences between
absolute values and percent predicted are obvi-
ously subtle it should be noted that a 6MWD of
450 m is approximately 80% predicted for a 6-year-
old and 65% predicted for a 13-year-old. As shown
previously,5,6 age and baseline walking ability are 2
important variables that determine decline in
ambulation as measured by 6MWT; there is a tend-
ency for the 6MWD to improve or be stable over
the first 7 years of age,5,6,8,9 and patients who have
lower initial 6MWD values and percent predicted
6MWD tend to show greater declines over the
course of 48 weeks. Patients 7 years of age may
show stable function or even improving function
over 48 weeks, but they are almost always those
with higher levels of baseline function (6MWD
>350 m or percent predicted 6MWD >60%). Con-
versely, patients with baseline 6MWD <350 m dem-
onstrate a greater decline in 6MWD over the 48-
week evaluation period (Fig. 5).
Baseline 6MWD has prognostic significance,
both for the primary assessment of bipedal ambu-
lation and for evaluation of secondary assessments
of activity, function, muscle strength, and fall fre-
quency. The 57-patient cohort had a mean base-
line 6MWD of 360 (SD 5 88) m. The baseline
range of 6MWD was 159–533 m, reflective of the
heterogeneous nature of the patient population (N
5 57, aged 5–15 years at study entry).
To assist clinical investigators with clinical trial
design, we have provided the mean and SD from
baseline to week 48 at 6-week intervals and the
Table 2. Placebo DMD patients with missing data and falls during 6MWT by visit in Study 007 (n 5 57).
Visit
Number of patients




tests with 1 falls
Median recovery time
(seconds) per 6MWT
taken for falls (range)
Screening 0 57 6 10.5 8.0 (2–44)
Baseline 0 57 5 8.8 3.0 (1–12)
Week 6 0 57 5 8.8 10.0 (7–26)
Week 12 1 56 2 3.6 4.0 (3–5)
Week 18 0 57 4 7.0 4.5 (3–6)
Week 24 0 57 2 3.5 3.5 (3–4)
Week 30 1 56 3 5.4 4.0 (3–23)
Week 36 4 53 2 3.8 14.0 (4–24)
Week 42 0 57 6 10.5 4.5 (2–17)





Total falls Total percent of
tests with 1 falls
Median recovery time
per 6MWT taken for falls
Totals 8 (1.6%) 505 (98.4%) 35 6.9% 5.0 (1-44)
6MWD, 6-minute walk distance.
*Missed tests 5 tests that were scheduled but not performed.
FIGURE 1. Change in strength for 5 strength measures by
myometry obtained every 6 weeks for 48 weeks (mean 6 SEM)
in DMD patients (n 5 57).
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corresponding mean and SD change from baseline
for both 6MWD and percent predicted 6MWD for
all subjects (Table 3), steroid-treated patients
(Table 4), and steroid-naive patients <7 years of
age (Table 5). As seen in Figure 6a and b, there
appears to have been be a progressive decline over
6-week intervals in mean 6MWD and predicted
6MWD. The effect of age on the progression of
endpoints is shown for mean 6MWD (Fig. 6c) and
mean percent predicted 6MWD (Fig. 6d) in
steroid-treated DMD patients. The effect of long-
term administration of glucocorticoid (6 months
of stable dosing) on changes in ambulatory
FIGURE 2. (a) Change in baseline time to stand from supine in
seconds (mean 6 SEM) for steroid-treated patients 7 years
old (n 5 32) and <7 years old (n 5 6) with DMD over 48 weeks
of evaluation. (b) Change in time to climb 4 stairs in seconds
(mean 6 SEM) for steroid-treated patients 7 years old (n 5
34) and <7 years old (n 5 6) with DMD over 48 weeks of eval-
uation. (c) Change in baseline time to run/walk 10 m in seconds
(mean 6 SEM) for steroid-treated patients 7 years old (n 5
34) and <7 years old (n 5 6) with DMD over 48 weeks of
evaluation.
FIGURE 3. Relationship between percent change in 6MWD and
percent change in 10-m run/walk test.
FIGURE 4. (a) Change in 6MWD over 48 weeks in 57 placebo-
treated DMD patients. (b) Change in percent predicted 6MWD
using age and height 2 calculated value over 48 weeks in 57
placebo-treated patients.
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function (assessed as change in 6MWD at 6-week
intervals over 48 weeks) is shown for <7-year-olds
(Fig. 7a) and 7-year-olds (Fig. 7b). Although
results are not statistically significant due to small
numbers, the effect of long-term steroids on ambu-
latory function appears to have been greater for
patients <7 years of age (Fig. 7a). In contrast, this
long-term steroid effect was not observed in
patients 7 years of age. Patients 7 years of age
either on steroids (n 5 34) or steroid-naive (n 5
9) exhibited similar declines in 6MWD over 48
weeks (Fig. 7b).
Time to Persistent 10% 6MWD Worsening. Using a
time-to-event approach, the time to persistent 10%
6MWD worsening is shown in Figure 8. The rela-
tive proportion of patients who reached the 10%
progression milestone appears to have been con-
stant over 48 weeks (26.3% of patients declined
10% or more during the first 24 weeks, and 23.8%
of the remaining patients declined 10% or more
from 24 to 48 weeks). This time-to-event approach
allows for determination of the time to disease pro-
gression relative to the patients’ baseline values
regardless of whether ambulation is lost and
patients have transitioned to a wheelchair.
Figure 9a–c shows the effect of baseline TFTs
on time to 10% progression in 6MWD. For all 3
TFTs there is a significant predicted value of time
to perform the task at baseline and proportion
progressing 10% on 6MWD. The effect of base-
line 6MWD and percent predicted 6MWD on the
proportion of patients who show persistent 10%
decline in 6MWD over the subsequent 48 weeks is
FIGURE 5. Change from baseline 6MWD in meters (mean 6
SEM) over 48 weeks by baseline 6MWD level (<350 m vs.
350 m).
FIGURE 6. (a) 6MWD in meters (mean 6 SEM) for all placebo-treated patients. (b) Percent predicted 6MWD (mean 6 SEM) using
age and height 2 calculated value for all placebo-treated patients. (c) Change in 6MWD in meters (mean 6 SEM) for steroid-treated
DMD patients <7 years old (n 5 6) and 7 years old (N 5 34). (d) Change in percent predicted 6MWD (mean 1 SEM) using age
and height 2 calculated value for steroid-treated DMD patients <7 years old (n 5 6) and 7 years old (N 5 34).
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shown in Figure 10a and b. Initial 6MWD of <325
m and <55% predicted were associated with a
greater likelihood of progressing 10% in 6MWD
over 48 weeks.
Prediction of Loss of Ambulation. Of the 57
patients, 15 (26.3%) did not have the ability to
stand from supine (within the allowed 30 s) at the
time of study entry. For the 15 who did not have
the ability to stand from supine at baseline, 6
(40%) lost ambulation over 48 weeks. In contrast,
only 1 of the 42 (2.3%) patients able to stand at
baseline subsequently lost the ability to ambulate
over the next 48 weeks (Fisher exact test, P <
0.0001). Six of 15 patients (40%) with baseline
6MWD <325 m lost ambulation over 48 weeks. In
contrast, 0 of 42 patients with baseline 6MWD 325
m lost ambulation (Fisher exact test, P < 0.0001).
DISCUSSION
Natural history data from this study regarding
the 6MWT and other clinical endpoints over 48
weeks provide information that is critically impor-
tant to the design of future clinical trials in ambula-
tory DMD. The 6MWT appears to be the most
sensitive available endpoint for clinical trials of ther-
apeutic agents targeted to stabilize function in
ambulatory DMD subjects6,11 in the clinical setting,
and TFTs also have a role as secondary endpoints
in ambulatory DMD clinical trials. These data dem-
onstrate that once ambulatory DMD patients deterio-
rate below a threshold 6MWD of 55% predicted or
approximately 325 m, a high percentage have a
decline of 10% in 6MWD over the subsequent year,
or even lose ambulation. The threshold value of
6MWD for risk of more rapid deterioration (325 m)
is 30 m below the mean 6MWD in our population
of ambulatory DMD (358 m) patients and the mean
6MWD previously reported in DMD,6,11 which sup-
ports the clinical significance of a 30-m decline in
6MWD. The distribution-based methods used to cal-
culate MCID that were applied to the 6MWD in
DMD also support an MCID of 30 m.11 In
dystrophin-deficient ambulatory boys there are impor-
tant maturational and disease-severity issues and
expected changes over 12 months of disease progres-
sion typically observed for specific endpoints. These
are all critical factors to consider in trial design.
Generalizability of Results. There have been no
studies suggesting DMD patients with nonsense
mutations in the dystrophin gene have a difference
in disease course when compared with DMD
patients with other types of mutations. The
patients in this study have a 1-year decline in
6MWD similar to previously described DMD
FIGURE 7. (a) 6MWD in meters (mean 6 SEM) for DMD
patients <7 years old treated with steroids (n 5 6) and steroid-
naive patients (N 5 8). (b) 6MWD in meters (mean 6 SEM) for
DMD patients 7 years old treated with steroids (N 5 34) and
steroid-naive subjects (N 5 9).
Table 3. Natural history of 6MWD and percent predicted 6MWD in placebo-treated patients (steroid-treated and non-steroid-treated
combined) evaluated every 6 weeks.
5 years Baseline 6 weeks 12 weeks 18 weeks 24 weeks 30 weeks 36 weeks 42 weeks 48 weeks
6MWD (m) n 57 57 56 57 57 56 53 57 55
Mean 361.1 358.8 354.3 355.2 346.5 345.3 342.4 331.5 317.4
SD 87.5 92.4 100.0 113.9 122.9 127.6 130.4 146.6 152.3
Mean D 0.0 –2.3 –7.2 –5.9 –14.6 –17.8 –22.5 –29.6 –44.1
SD D 0.0 30.1 36.8 49.6 61.2 64.3 68.9 85.4 88.0
6MWD percent
predicted
n 57 57 55 56 57 56 53 56 55
Mean 61.6 61.5 61.1 60.9 59.5 59.3 58.8 57.9 54.4
SD 16.3 17.3 18.3 21.0 22.5 22.9 23.4 25.3 27.0
Mean D 0.0 –0.1 –0.9 –0.8 –2.2 –2.8 –3.5 –4.3 –7.3
SD D 0.0 5.7 7.0 8.9 10.8 11.2 11.8 14.1 15.0
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patients without nonsense mutations.6 Mazzone
and colleagues reported a 242.3-m decline in
6MWD among DMD subjects >7 years of age.
Those in this age range who were on either no ste-
roids or intermittent regimens showed a 266.4-m
decline, and those on daily steroids showed a
223.6-m decline.9 In another study, mean 12-
month changes in 6MWD in a cohort in which
94% of subjects were treated with steroids was 244
(89) m among those with the TG/GG osteopontin
SPP1 genotype and 28 (61) m among those with
the TT SPP1 genotype.27 Although Becker muscu-
lar dystrophy (BMD) patients could theoretically
have been included in our study, the study popula-
tion was primarily DMD patients, given the inclu-
sion criteria of more severe disease phenotype
(i.e., onset of characteristic symptoms or signs of
proximal weakness, waddling gait, and Gower
maneuver by 9 years of age) and ongoing difficulty
with ambulation at study entry.
There are currently no treatments for the
underlying cause of DMD. Glucocorticoids (e.g.,
prednisone or deflazacort) are the only pharmaco-
logic therapy demonstrated to be effective in tem-
porarily reducing the decline in motor function in
patients with DMD.19,28 Of note, in the natural his-
tory data from this study, the proportion of
patients on glucocorticoids (70.2%) is similar to
that of patients with DMD treated with glucocorti-
coids at baseline (210 of 340 5 62%) in the con-
temporary Cooperative International
Neuromuscular Research Group (CINRG) natural
history study.29 In the multistate population-based
series from the U.S. Centers of Disease Control
based on all patients (ambulatory and non-ambula-
tory) 50% were on glucocorticoids.30
Implication of Maturational Issues and Severity of
Disease at Baseline for Future Design of Clinical
Trials. Studies have documented that the expected
changes over time in both TFTs and 6MWD are
strongly influenced by age, baseline ambulatory
function, and maturational issues.6,9,31,32 The data
we have presented on mean 6MWD, SD, mean
change in 6MWD from baseline, and SD of the
change in 6-week intervals over 48 weeks should be
helpful for clinical trial planning. Stratification of
patients is important to ensure the groups are bal-
anced not only for age, but for baseline 6MWD and
corticosteroid use.
The reliability of clinical measurement becomes
more challenging in children <5 years of age. Our
natural history data suggest that clinical trials in boys
<7 years of age will need to: (a) be limited to thera-
peutic agents that will produce an effect of improving
function rather than stabilizing function; (b) consider
impairment values relative to age-matched controls;
(c) be carried out over durations of >1 year so that
disease progression may be measured; and/or (d)
employ alternative candidate surrogate endpoints
that can be measured reliably in young children.
In addition, we need to be mindful that some
therapeutic agents in DMD are likely to require suf-
ficient viable muscle fibers to be effective. For
example, results published or presented from exon-
skipping trials suggest that patients with better ini-
tial 6MWD (340–350 m or >50–55% predicted
6MWD estimated from data presented) may be




















n 6 6 6 6 6 6 6 6 6
Mean 382.8 417.3 413.5 425.5 418.0 410.1 405.9 427.6 416.9
SD 42.7 55.1 30.7 30.7 32.9 25.9 35.6 40.6 35.1
Mean D 0.0 34.5 30.7 42.7 35.2 27.4 23.1 44.8 34.1




n 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0
Mean 72.1 78.6 78.0 80.0 78.5 76.9 76.1 80.2 77.9
SD 6.8 9.4 6.7 5.9 7.7 5.1 8.8 9.8 8.3
Mean D 0.0 6.4 5.8 7.8 6.4 4.8 4.0 8.0 5.8
SD D 0.0 7.2 7.6 5.5 10.4 6.4 12.4 12.4 10.5
7 years
6MWD (m) n 34 34 34 34 34 33 31 34 33
Mean 356.1 345.7 340.1 342.7 330.8 332.8 331.9 307.5 297.1
SD 93.6 96.6 101.1 114.0 128.3 134.7 137.2 156.5 154.5
Mean D 0.0 –10.5 –16.1 –13.4 –25.3 –26.5 –32.1 –48.6 –58.9




n 34.0 34.0 33.0 33.0 34.0 33.0 31.0 34.0 33.0
Mean 58.5 57.2 57.0 56.6 54.8 55.3 55.1 51.0 49.4
SD 16.7 17.0 17.7 20.3 22.3 23.3 23.7 26.8 26.3
Mean D 0.0 –1.3 –2.1 –2.0 –3.7 –3.9 –4.8 –7.6 –9.3
SD D 0.0 5.8 7.0 8.2 10.5 11.7 11.8 14.9 13.9
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more likely to demonstrate better response to treat-
ment.33,34 Thus, the likelihood that a critical pro-
portion of viable muscle fibers must be present for
a treatment that induces more dystrophin expres-
sion to be efficacious needs to be balanced against
the challenge of showing a treatment effect if the
population is higher functioning at baseline and
less likely to show deterioration over 12 months.
Useful serum surrogate biomarkers have not
been identified for DMD, and both MR imaging bio-
markers and measures of dystrophin expression on
muscle biopsy have not been validated sufficiently to
be employed as primary clinical trial endpoints. In
the absence of an adequate surrogate endpoint,
future clinical trials on the ambulatory DMD popula-
tion need careful trial design with optimal inclusion
and exclusion criteria (age, baseline 6MWD or per-
cent predicted 6MWD, standing times, stable regi-
mens of glucocorticoids, etc.), judicious choice of
endpoints expected to be responsive to treatment,
and adequate estimates of statistical power using
clinically meaningful treatment effect sizes.
Importance of Establishing the Connection between
Change in 10-Meter Run/Walk and 6MWD. The 10-m
run/walk is a measure that is easily obtained by the
clinician in the outpatient clinic setting. We have
shown that, on average, a 6-s performance on the
10-m run/walk (1.64 m/s) corresponds to 358 m
on the 6MWT.11 In addition, a time of <6 s on the
10-m run/walk is associated with continued ambula-
tion over the subsequent 12 months, and a time of
>10–12 seconds is associated with a high risk of loss
of ambulation over 12 months.31 Furthermore, data
from the CINRG Duchenne Natural History Study
demonstrated that a 10% decline in ambulatory
function, as measured by the 10-m run/walk, is pre-
dictive of the number of months to loss of ambula-
tion over 4 years.29,32 Thus, our current data, which
show a high correlation between percent change in
10-m run/walk and percent change in 6MWD, sug-
gest that a 10% change in ambulatory function, as
measured by the 6MWT, would have similar clinical
meaning in predicting loss of ambulation.
Variability of Change in Endpoints over 48
Weeks. The results indicate that the 6MWT is, at
present, the most reliable clinical endpoint requir-
ing the smallest patient population for power. Pre-
viously there has been concern regarding the
increasing standard deviation of the mean 6MWD,
mean change in 6MWD in DMD over 48 weeks
(Fig. 6), and the impact this increasing variability
has on statistical power. It is important to note
that all the TFTs also show increasing variability
from baseline to 48 weeks, as measured by the
standard deviation, standard error, and coefficient
of variation, for mean values and mean change
from baseline (Fig. 2). Strength measures using
myometry also show increased SD and SEM values
(Fig. 1) and mean change values over 48 weeks
(not shown). Thus, the increasing variability is not
an inherent problem with the clinical endpoints
but rather represents the variability of disease pro-
gression in DMD that is an inherent aspect of the
disease. This issue can be addressed by studying an
appropriate sample size in clinical trials, calculated
based on the variability of the endpoint. Further, it
can be mitigated partly by including only patients
Table 5. The 48-week natural history data of 6MWD in placebo group patients (non-steroid-treated) evaluated every 6 weeks.
<7 years Baseline 6 weeks 12 weeks 18 weeks 24 weeks 30 weeks 36 weeks 42 weeks 48 weeks
6MWD (m) n 8 8 7 8 8 8 7 8 7
Mean 366.3 364.2 364.4 372.1 381.5 365.3 368.6 379.4 341.4
SD 63.5 62.1 63.4 73.8 80.0 91.2 90.7 81.1 163.9
Mean D 0.0 –2.1 –5.4 5.8 15.1 –1.1 9.9 13.1 –28.4
SD D 0.0 19.2 18.5 45.8 51.5 56.8 61.5 46.7 128.6
6MWD percent
predicted
n 8 8 7 8 8 8 7 8 7
Mean 70.1 69.3 69.2 70.8 72.6 69.4 69.9 71.9 64.7
SD 11.5 11.2 11.6 14.1 15.7 17.5 17.2 15.2 30.7
Mean D 0.0 –0.7 –1.3 0.8 2.5 –0.7 1.5 1.9 –5.8
SD D 0.0 3.6 3.6 8.4 9.7 10.4 11.3 8.5 23.3
FIGURE 8. Time to persistent 10% 6MWD worsening in 57
DMD patients. Note that the relative proportion of patients who
reached the 10% progression milestone was constant over 48
weeks (26.3% patients declined 10% or more during the first 24
weeks; 23.8% of the remaining patients declined 10% or more
from weeks 24–48).
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on standard long-term steroid regimens and choos-
ing inclusion criteria that produce more homoge-
neous populations.
Strength Measures as Clinical Endpoints in
DMD. The decline in strength was minimal over
the course of the study. The greatest change in
strength by myometry at 48 weeks, which occurred
for knee extension, was lower than the previously
calculated MCID for knee extension in DMD of
2.1 pounds (standard error of measurement
method) and 2.4 pounds using the one-third of
baseline SD method.11,35–37 Thus, in DMD a treat-
ment that produces a therapeutic effect in strength
over 48 weeks that would be greater than the
MCID would at least need to produce small
increases in strength in the functional muscle
groups rather than reduction in decline in
strength. Therefore, these data do not support the
use of absolute values of strength by myometry as
endpoints in ambulatory DMD unless the treat-
ment under investigation is anticipated to produce
a short-term increase in absolute strength values,
such as that reported for glucocorticoids. An agent
that stabilizes or slows decline in strength and
would not be expected to increase strength, as
anticipated for dystrophin restoration therapy,
would require a longer duration trial. Part of the
limitation in strength measurement is the lack of
normative and percent predicted values for age.
The other important limitation of strength mea-
surement pertains to the floor effect of lower-
FIGURE 9. (a) Kaplan–Meier analysis of time to 10% progres-
sion in 6MWD by time to stand for 3 groups (time to stand <4
s, 4 to < 8 s, and 8 s/cannot stand). (b) Kaplan–Meier analy-
sis of time to 10% worsening in 6MWD by time to climb 4 stairs
for 3 groups (time to climb 4 stairs <3 s, 3 to <6 s, and 6 s/
cannot climb). (c) Kaplan–Meier analysis of time to 10% wor-
sening in 6MWD by time to run/walk 10 m for 3 groups (10-m
run/walk <5 s, 5 to <10 s, and 10 seconds).
FIGURE 10. (a) Kaplan–Maier survival for time to 10% progres-
sion on 6MWD for 3 groups, based on initial 6MWD (<325 m,
325 to <410 m, and 410 m). (b) Kaplan–Meier analysis of
time to 10% worsening in 6MWD based on initial percent pre-
dicted 6MWD at baseline for 3 groups (percent predicted
6MWD <55%, percent predicted 6MWD 55% to <80%, and
percent predicted 6MWD 80%).
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extremity strength values typically seen in DMD
patients 7 years of age, which are low at base-
line11 and decline minimally over 48 weeks.
TFTs as Clinical Endpoints in DMD. TFTs appear to
have some potential utility in DMD clinical trials.
TFTs that measure maximal burst activity are read-
ily obtainable by the clinician in an outpatient set-
ting, and they appear to predict the likelihood of a
10% progression in ambulatory function and loss
of ambulatory function over the subsequent year
(Fig. 9). It is not surprising that the threshold
timed function values for predicting 10% progres-
sion in 6MWD are lower than the threshold values
for predicting later loss of ambulation.32
Natural history data from CINRG and this study
have shown that a standing time of >8 s predicts
10% progression over a year, but inability to stand
(within 30 s) predicts a higher likelihood of loss of
ambulation over 12 months. A >6-s time to climb
4 stairs is predictive of a greater likelihood of 10%
progression in the 6MWD, whereas a >8-s stair
climb predicts greater likelihood of loss of ambula-
tion over 12 months.32 A 5-s 10-m run/walk time
predicts time to 10% progression in 6MWD,
whereas a >10–12-s 10-m run/walk time predicts
loss of ambulation over 12 months.31,32
Ability to stand is a useful prognostic indicator
for continued ambulation over 12 months, giving
it utility as a potential inclusion criterion for a clin-
ical trial. However, in trials of 12 months or
shorter duration we would not recommend stand-
ing time as an endpoint for patients younger than
age 7 years unless the therapeutic agent would be
expected to improve standing time. The use of
standing time as an endpoint in patients aged 7
years is limited by the significant proportion of
subjects who cannot perform the functional task.
Whereas time to climb 4 stairs did not change
for steroid-treated children <7 years of age, this
measure showed a mean change of 4.7 6 7.5 s for
steroid-treated patients 7 years of age (greater
than the MCID of 2.1–2.2 s for time to climb 4
stairs).12 Thus, stabilization of this measure over 12
months would be a clinically meaningful outcome.
In addition, time to climb 4 stairs shows high test–
retest reliability and the highest correlation (0.67)
of any TFT measure with knee extension strength.11
Time to run/walk 10 m is a burst measure of
ambulatory function rather than an endurance
measure. Although the change over 12 months in
10-m run/walk was greater than the MCID of 1.4–
2.3 s,11 the MCID/baseline mean ratio was much
higher for the 10 m run/walk test (0.19–0.31) ver-
sus that for the 6MWD (0.08–0.09), and the test–
retest reliability for the 10-m run/walk test was
demonstrated previously to be lower than that for
the 6MWT.11 Thus, as a clinical endpoint for trials,
the 6MWD appears to have advantages as a more
reliable and sensitive measure of change in ambu-
latory function compared with the shorter-interval
10-m run/walk test.
Ambulation Declines more Precipitously in DMD Once
a Threshold Level of Impairment Is Reached. In
DMD, it is noteworthy that reduced 6MWD and per-
cent predicted 6MWD values below 50–55% pre-
dicted (based on age and height) are associated with
significant continued declines in ambulatory function
as measured by the 6MWD, despite relatively small
concomitant changes in knee extension strength val-
ues, which have reached a floor effect.11 In addition,
with slowing of ambulation velocity and continued
decrease in percent predicted 6MWD to <50–55%
there is a precipitous increase in the energy cost of
locomotion as measured by the Energy Expenditure
Index.11 This may account for the more precipitous
loss of ambulatory function that occurs in a signifi-
cant percent of patients who have absolute 6MWD
and percent predicted 6MWD values of <325 m and
50–55% predicted, respectively.
A Change in 6MWD of 30 Meters Is Clinically
Meaningful. Our data support the concept of a 30-
m change in 6MWD being clinically meaningful.
The MCIDs calculated from statistical distribution
methods indicates that 30 m is a meaningful
change.11 A 10% decline in ambulation over 12
months is associated with significantly greater like-
lihood of lost ambulation over the next 4 years32
and, given a typical baseline 6MWD of 350 m, a
30-m change to 320 m (which approaches a 10%
change) places patients below a threshold level of
function where they become at risk for losing
ambulation. In addition, boys with DMD encounter
considerable ambulatory challenges in their daily
life that are clinically important. The distance of
30 m may have real-world significance in terms of
keeping up with peers, distances required to get
from a parking lot into a school, travel to a bus
stop, or make it to a restroom. Data from placebo-
controlled studies of laronidase for mucopolysac-
charidosis type I (MPS I), idursulfase for MPS II,
bosentan for primary pulmonary hypertension,
and alglucosidase-a for Pompe disease also support
the clinical meaningfulness of a 30-m treatment
effect for the 6MWT.37–40 In these studies, differ-
ences in mean changes in 6MWD in drug-treated
patients versus placebo-treated patients ranged
from 28 to 44 m.37–40 The data from the trials in
MPS I, MPS II, and Pompe disease are especially
relevant given that the limitations on patient activ-
ity in these diseases and those in DMD result from
disease-related impairments in both the neuromus-
cular and pulmonary systems. Strikingly, when
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accepted MCID thresholds of other diseases (as
low as 5% change)41 are applied to the mean base-
line 6MWD of this study, an 18-m change would be
considered clinically meaningful. This further
emphasizes that 30 m would be a robust measure
of clinical meaningfulness in evaluation of 6MWD
and would exceed the MCID for 6MWD from mul-
tiple accepted methodologies in other diseases.
In conclusion, in this study we have confirmed
the 6MWT to be safe and feasible in DMD. Our
findings support the clinically meaningful change
in 6MWD to be in the range of 20–30 m, which
can serve as the targeted treatment effect in 12-
month trials in ambulatory DMD. Baseline 6MWD
was found to be predictive of time to 10% wor-
sening in function, a clinically meaningful mile-
stone. A 10% decline in ambulatory function, as
measured by the 10-m run/walk over 1 year, has
been shown recently to be predictive of time to
loss of ambulation over the subsequent 4 years.35
The close association between the percent change
in time to run/walk 10 m and percent change in
6MWD also supports the notion that a 10% change
in 6MWD is clinically meaningful and predictive of
loss of ambulation. Finally, it appears that a
decline of approximately 30 m from an average
performance on the 6MWT in DMD to a threshold
6MWD of 325 m or 55% predicted would place a
patient at risk for a more precipitous decline in
ambulatory function over the subsequent year.
Given the limitations of other measures in DMD,
including surrogate biomarkers, strength by myo-
metry, TFTs, and patient-reported outcome meas-
ures, the 6MWD is the recommended primary
outcome measure in ambulatory DMD.
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